Chimeric Therapeutics LimitedASX: CHM

Phase 1B CHM CORE-NK trial advances to newly diagnosed AML

Dec 16, 2024 at 4:09 AM UTC · Issued by Chimeric Therapeutics Limited

Chimeric Therapeutics Ltd has released a press release.

View Attachment